Compare HTO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTO | PGEN |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | HTO | PGEN |
|---|---|---|
| Price | $47.94 | $3.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $58.00 | $7.67 |
| AVG Volume (30 Days) | 401.6K | ★ 4.4M |
| Earning Date | 10-27-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 14.49 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $804,224,000.00 | $6,309,000.00 |
| Revenue This Year | $9.75 | $342.78 |
| Revenue Next Year | $8.19 | $478.46 |
| P/E Ratio | $15.09 | ★ N/A |
| Revenue Growth | 11.39 | ★ 59.20 |
| 52 Week Low | $43.75 | $0.65 |
| 52 Week High | $57.17 | $5.23 |
| Indicator | HTO | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 44.22 |
| Support Level | $43.75 | $3.44 |
| Resistance Level | $48.42 | $3.92 |
| Average True Range (ATR) | 1.15 | 0.30 |
| MACD | 0.34 | -0.06 |
| Stochastic Oscillator | 90.04 | 11.54 |
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.